Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has accepted for review a biologics license application seeking the approval of tislelizumab for use in the frontline treatment of patients with unresectable, recurrent, locally advanced or metastatic esophageal squamous cell carcinoma.
PredicineBEACON™ and PredicineWES+™ were used to detect and monitor a diverse spectrum of genomic alternations and emerging resistance mechanisms in...
HAYWARD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine
European Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma U.S. FDA accepts Biologics License Application in first-line advanced ESCC ...
19.09.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA ... Seite 1